Skip to main content

Advertisement

Springer Nature Link
Log in

Analysis of T-cell and Humoral Immune Response to SARS-CoV-2 Antigens in Rituximab-Treated Patients with Rheumatoid Arthritis Vaccinated with Combined Vector Vaccine Gam-COVID-Vac

  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

The COVID-19 pandemic has brought significant changes in managing of patients with rheumatoid arthritis. Rituximab-treated patients were more susceptible to severe infection. This required a “switch” to another genetically engineered drug in the patients with high risk of adverse COVID-19. In this study, we assessed the severity of immune response to SARS-CoV-2 antigens in rituximab-treated patients with rheumatoid arthritis vaccinated with the combined vector vaccine Gam-COVID-Vac. Insufficient formation of the humoral response and a high level of T-cell response to SARS-CoV-2 antigens in this group of patients were revealed. An imbalance of cellular and humoral response may play a role in more severe COVID-19 in rituximab-treated patients with rheumatoid arthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Jang S, Kwon EJ, Lee JJ. Rheumatoid arthritis: pathogenic roles of diverse immune cells. Int. J. Mol. Sci. 2022;23(2):905. doi: https://doi.org/10.3390/ijms23020905

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hyrich KL, Machado PM. Rheumatic disease and COVID-19: epidemiology and outcomes. Nat. Rev. Rheumatol. 2021;17(2):71-72. doi: https://doi.org/10.1038/s41584-020-00562-2

    Article  CAS  PubMed  Google Scholar 

  3. D’Silva KM, Wallace ZS. COVID-19 and disease-modifying anti-rheumatic drugs. Curr. Rheumatol. Rep. 2021(23):5:28. https://doi.org/10.1007/s11926-021-00998-9

  4. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun. Rev. 2020;19(5):102523. doi: https://doi.org/10.1016/j.autrev.2020.102523

    Article  CAS  Google Scholar 

  5. Korolev MA, Letyagina EA, Sizikov AE, Bogoderova LA, Ubshaeva YB, Omelchenko VO, Akimova AA, Mullagaliev AA, Chumasova OA, Kurochkina YD. Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs. Ter. Arkh. 2022;94(5):636-641. doi: https://doi.org/10.26442/00403660.2022.05.201502

    Article  CAS  PubMed  Google Scholar 

  6. Nasonov EL, Beketova TV, Reshetnyak TM, Lila AM, Ananieva LP, Lisitsyna TA, Soloviev SK. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Nauch. Prakt. Revmatol. 2020;58(4):353-367. Russian. https://doi.org/10.47360/1995-4484-2020-353-367

  7. Korolev MA, Ubshaeva YuB, Banshchikova NY, Letyagina EA, Mullagaliev AA. The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (ambira study). Nauch. Prakt. Revmatol. 2020;58(6):663-672. Russian. https://doi.org/10.47360/1995-4484-2020-663-672

  8. Bruchfeld A, Kronbichler A, Alberici F, Fervenza FC, Jayne DRW, Segelmark M, Tesar V, Szpirt WM. COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. Nephrol. Dial Transplant. 2021;36(9):1758-1760. doi: https://doi.org/10.1093/ndt/gfab174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Madelon N, Lauper K, Breville G, Sabater Royo I, Goldstein R, Andrey DO, Grifoni A, Sette A, Kaiser L, Siegrist CA, Finckh A, Lalive PH, Didierlaurent AM, Eberhardt CS. Robust T-cell responses in anti-CD20-treated patients following COVID-19 vaccination: a prospective cohort study. Clin. Infect. Dis. 2022;75(1):e1037-e1045. doi: https://doi.org/10.1093/cid/ciab954

    Article  PubMed  Google Scholar 

  10. Picchianti-Diamanti A, Aiello A, Laganà B, Agrati C, Castilletti C, Meschi S, Farroni C, Lapa D, Najafi Fard S, Cuzzi G, Cimini E, Grassi G, Vanini V, Di Rosa R, Salemi S, Nalli G, Salmi A, Repele F, Altera AMG, Maffongelli G, Palazzolo C, Vita S, Leone S, Puro V, Capobianchi MR, Ippolito G, Nicastri E, Goletti D. Immunosuppressive therapies differently modulate humoral- and T-cell-specific responses to COVID-19 mRNA vaccine in rheumatoid arthritis patients. Front. Immunol. 2021;12:740249. doi: https://doi.org/10.3389/fimmu.2021.740249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bertoletti A, Le Bert N, Qui M, Tan AT. SARS-CoV-2-specific T cells in infection and vaccination. Cell. Mol. Immunol. 2021;18(10):2307-2312. doi: https://doi.org/10.1038/s41423-021-00743-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Connective Tissue Pathology, Research Institute of Clinical and Experimental Lymphology — Branch of the Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia

    V. O. Omelchenko, Yu. D. Kurochkina, A. V. Fedorova, V. S. Ovchinnikov, V. V. Koval, I. V. Bratko, E. A. Letyagina & M. A. Korolev

Authors
  1. V. O. Omelchenko
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Yu. D. Kurochkina
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. A. V. Fedorova
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. V. S. Ovchinnikov
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. V. V. Koval
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. I. V. Bratko
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. E. A. Letyagina
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. M. A. Korolev
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to V. O. Omelchenko.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 176, No. 12, pp. 762-767, December, 2023

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Omelchenko, V.O., Kurochkina, Y.D., Fedorova, A.V. et al. Analysis of T-cell and Humoral Immune Response to SARS-CoV-2 Antigens in Rituximab-Treated Patients with Rheumatoid Arthritis Vaccinated with Combined Vector Vaccine Gam-COVID-Vac. Bull Exp Biol Med 176, 786–790 (2024). https://doi.org/10.1007/s10517-024-06109-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-024-06109-9

Keywords